Morgan Stanley Immunic, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Immunic, Inc. stock. As of the latest transaction made, Morgan Stanley holds 567,612 shares of IMUX stock, worth $527,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares

567,612

Previous 1,104,756 48.62%

Holding current value

$527,879

Previous $1.1 Million 44.02%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.94 - $1.3 $504,915 - $698,287	-537,144 Reduced 48.62%	567,612 $618,000
Q4 2024 Feb 14, 2025	BUY	$1.0 - $1.61 $714,046 - $1.15 Million	714,046 Added 182.76%	1,104,756 $1.1 Million
Q3 2024 May 14, 2025	BUY	$1.08 - $1.95 $394,530 - $712,346	365,306 Added 1437.99%	390,710 $644,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.95 $394,530 - $712,346	365,306 Added 1437.99%	390,710 $644,000
Q2 2024 May 14, 2025	SELL	$0.98 - $1.44 $1.06 Million - $1.55 Million	-1,079,352 Reduced 97.7%	25,404 $28,000
Q2 2024 Oct 17, 2024	SELL	$0.98 - $1.44 $4,806 - $7,063	-4,905 Reduced 16.18%	25,404 $28,000
Q2 2024 Aug 14, 2024	SELL	$0.98 - $1.44 $4,806 - $7,063	-4,905 Reduced 16.18%	25,404 $28,000
Q1 2024 Oct 17, 2024	BUY	$1.14 - $1.53 $5,591 - $7,504	4,905 Added 19.31%	30,309 $40,000
Q1 2024 Aug 16, 2024	BUY	$1.14 - $1.53 $15,873 - $21,303	13,924 Added 84.98%	30,309 $40,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $15,873 - $21,303	13,924 Added 84.98%	30,309 $40,000
Q4 2023 Aug 16, 2024	SELL	$0.97 - $1.6 $8,748 - $14,430	-9,019 Reduced 35.5%	16,385 $24,000
Q4 2023 Feb 13, 2024	SELL	$0.97 - $1.6 $15,237 - $25,134	-15,709 Reduced 48.95%	16,385 $24,000
Q3 2023 Nov 15, 2023	SELL	$1.35 - $2.87 $33,764 - $71,781	-25,011 Reduced 43.8%	32,094 $47,000
Q2 2023 Aug 14, 2023	SELL	$1.33 - $2.51 $621,602 - $1.17 Million	-467,370 Reduced 89.11%	57,105 $143,000
Q1 2023 May 15, 2023	BUY	$1.35 - $2.87 $67,632 - $143,781	50,098 Added 10.56%	524,475 $781,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $515,835 - $4.93 Million	456,492 Added 2552.37%	474,377 $664,000
Q3 2022 Nov 14, 2022	SELL	$3.0 - $5.49 $64,056 - $117,222	-21,352 Reduced 54.42%	17,885 $56,000
Q2 2022 Oct 27, 2022	BUY	$3.13 - $12.25 $48,286 - $188,980	15,427 Added 64.79%	39,237 $136,000
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $48,286 - $188,980	15,427 Added 64.79%	39,237 $136,000
Q1 2022 Oct 27, 2022	SELL	$9.54 - $14.26 $147,173 - $219,989	-15,427 Reduced 39.32%	23,810 $269,000
Q1 2022 May 13, 2022	SELL	$9.54 - $14.26 $337,792 - $504,918	-35,408 Reduced 59.79%	23,810 $269,000
Q4 2021 Feb 14, 2022	BUY	$7.34 - $10.25 $355,498 - $496,438	48,433 Added 449.08%	59,218 $567,000
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $86,819 - $143,332	10,785 New	10,785 $95,000

Others Institutions Holding IMUX

# of Institutions

Shares Held

47M

Call Options Held

1.14M

Put Options Held

130K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $28.4M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account